Albert Lowe
Stock Analyst at Craig-Hallum
(1.79)
# 3,139
Out of 4,876 analysts
9
Total ratings
44.44%
Success rate
2.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Initiates: Buy | $50 | $16.21 | +208.45% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.88 | +354.80% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $0.98 | +514.38% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $4.11 | +240.63% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $1.73 | +535.84% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $3.15 | +153.97% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $0.94 | +327.72% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.05 | +471.43% | 1 | May 13, 2024 |
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $16.21
Upside: +208.45%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.88
Upside: +354.80%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $0.98
Upside: +514.38%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $4.11
Upside: +240.63%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $1.73
Upside: +535.84%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $3.15
Upside: +153.97%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $0.94
Upside: +327.72%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.05
Upside: +471.43%